Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen and Watson Pharmaceuticals have announced a collaboration to develop and commercialize various oncology antibody biosimilar medicines across the globe.
Subscribe to our email newsletter
According to both the companies commercialization of biosimilar products will not follow a pure brand or generic model.
As per the collaboration, Amgen will take up developing, manufacturing and initially commercializing the oncology antibody products.
Watson, on the other hand, will contribute up to $400m in co-development costs over the course of development, including the provision of development support, and will share product development risks.
The products under the deal are likely to be sold under a joint Amgen/Watson label.
Watson will initially receive royalties and sales milestones from product revenues and the collaboration will not pursue biosimilars of Amgen’s proprietary products.